Achieve Life Sciences

Achieve Life Sciences is a biopharmaceutical company that develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The Company is also working on cytisine-based therapies as a widely available treatment option for nicotine addiction.

SEATTLE and VANCOUVER, British Columbia, Dec. 9, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

SEATTLE and VANCOUVER, British Columbia, Oct. 31, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today...

SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their...

SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two...

Achieve Life Sciences Blogs

SEATTLE, Wash. And VANCOUVER, British Columbia, December 19, 2019 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing…

SEATTLE, Wash. and VANCOUVER, British Columbia, December 9, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced an update o…

SEATTLE, Wash. and VANCOUVER, British Columbia, October 31, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it wil…

SEATTLE, Wash. and VANCOUVER, British Columbia, October 24, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that data f…

SEATTLE, Wash. and VANCOUVER, British Columbia, September 13, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring…

SEATTLE, Wash. and VANCOUVER, British Columbia, July 30, 2019 -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its second quarte…